Aviso Financial Inc. Grows Stake in IQVIA Holdings Inc. (NYSE:IQV)

Aviso Financial Inc. boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 129,467 shares of the medical research company’s stock after purchasing an additional 4,222 shares during the quarter. IQVIA comprises about 1.3% of Aviso Financial Inc.’s portfolio, making the stock its 23rd biggest position. Aviso Financial Inc. owned 0.07% of IQVIA worth $25,442,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of IQV. Impax Asset Management Group plc increased its holdings in IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after purchasing an additional 157,809 shares during the period. Assetmark Inc. increased its holdings in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Covestor Ltd increased its holdings in IQVIA by 34.4% during the 3rd quarter. Covestor Ltd now owns 246 shares of the medical research company’s stock worth $59,000 after purchasing an additional 63 shares during the period. Ashton Thomas Securities LLC bought a new stake in IQVIA during the 3rd quarter valued at $57,000. Finally, Apollon Wealth Management LLC boosted its position in IQVIA by 9.6% during the 3rd quarter. Apollon Wealth Management LLC now owns 4,874 shares of the medical research company’s stock valued at $1,155,000 after acquiring an additional 427 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 2.1 %

IQVIA stock opened at $181.53 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The business’s 50-day simple moving average is $196.87 and its two-hundred day simple moving average is $211.38. The company has a market cap of $32.01 billion, a PE ratio of 24.20, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.76.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IQV. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Morgan Stanley increased their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Bank of America dropped their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Finally, UBS Group dropped their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.